Is BRRGF or DIVO a better dividend investment in 2026?

BRRGF currently yields 2.06% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: DIVO offers higher current income.

What is the dividend yield difference between BRRGF and DIVO?

BRRGF has a forward dividend yield of 2.06% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 4.43 percentage points.

Home › Compare › BRRGF vs DIVO

BRRGF vs DIVO: Dividend Comparison 2026

BRRGF yields 2.06% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 DIVO wins by $8.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

BRRGF

● Live price

2.06%

Share price

$97.09

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.7K

Annual income

$235.33

Full BRRGF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — BRRGF vs DIVO

📍 DIVO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BRRGF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BRRGF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BRRGF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRRGF

Annual income on $10K today (after 15% tax)

$175.09/yr

After 10yr DRIP, annual income (after tax)

$200.03/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, DIVO beats the other by $634.40/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRRGF + DIVO for your $10,000?

BRRGF: 50%DIVO: 50%

100% DIVO50/50100% BRRGF

Portfolio after 10yr

$26.7K

Annual income

$608.51/yr

Blended yield

2.28%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BRRGF right now

BRRGF

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

2821.3

Piotroski

2/9

DIVO

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRRGF buys

DIVO buys

No recent congressional trades found for BRRGF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBRRGFDIVO

Forward yield	2.06%	6.49% ✓
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$22.7K	$30.7K ✓
Annual income after 10y	$235.33	$981.68 ✓
Total dividends collected	$2.2K	$8.2K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BRRGF vs DIVO ($10,000, DRIP)

Year	BRRGF Portfolio	BRRGF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$10,906	$205.99	$11,349	$649.42	$443.00 → DIVO
2	$11,879	$209.95	$12,833	$688.83	$954.00 → DIVO
3	$12,925	$213.73	$14,459	$727.90	$1.5K → DIVO
4	$14,047	$217.32	$16,238	$766.49	$2.2K → DIVO
5	$15,251	$220.74	$18,179	$804.47	$2.9K → DIVO
6	$16,542	$223.98	$20,293	$841.71	$3.8K → DIVO
7	$17,927	$227.05	$22,591	$878.14	$4.7K → DIVO
8	$19,412	$229.97	$25,087	$913.65	$5.7K → DIVO
9	$21,004	$232.72	$27,791	$948.18	$6.8K → DIVO
10	$22,709	$235.33	$30,718	$981.68	$8.0K → DIVO

BRRGF vs DIVO: Complete Analysis 2026

BRRGF — Stock

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Full BRRGF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this BRRGF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRRGF vs SCHD BRRGF vs JEPI BRRGF vs O BRRGF vs KO BRRGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.